
NASDAQHealthcareBiotechnology
Latest quote
$28.40
−$0.30 · -1.05%
Avalyn Pharma Inc. operates as a biopharmaceutical firm currently in its clinical development phase. The company's primary focus is on creating inhaled pharmaceutical products to manage rare lung conditions, including pulmonary fibrosis and various other interstitial lung diseases (ILDs). Richard Glenn Vincent, Mark W. Surber, and Michael J. Kamdar co-founded the enterprise on May 27, 2011, and its corporate headquarters are situated in Boston, Massachusetts.
Previous close
$28.40
−$0.30 · -1.05%
Regular session · ET · Market data may be delayed.
Avalyn Pharma Inc. operates as a biopharmaceutical firm currently in its clinical development phase. The company's primary focus is on creating inhaled pharmaceutical products to manage rare lung conditions, including pulmonary fibrosis and various other interstitial lung diseases (ILDs). Richard Glenn Vincent, Mark W. Surber, and Michael J. Kamdar co-founded the enterprise on May 27, 2011, and its corporate headquarters are situated in Boston, Massachusetts.
Day range
Current $28.40
52-week range
Current $28.40
Regular session · ET · Market data may be delayed.
GoAI Score
Hold
Valuation
40
Expensive
Sentiment
61
Bullish
Risk
48
Elevated Risk
Momentum
39
Weakening
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Avalyn Pharma Inc. operates as a biopharmaceutical firm currently in its clinical development phase. The company's primary focus is on creating inhaled pharmaceutical products to manage rare lung conditions, including pulmonary fibrosis and various other interstitial lung diseases (ILDs). Richard Glenn Vincent, Mark W. Surber, and Michael J. Kamdar co-founded the enterprise on May 27, 2011, and its corporate headquarters are situated in Boston, Massachusetts.
Day range
Current $28.40
52-week range
Current $28.40
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 |
|---|---|---|
| Research and development | 76.61M USD | 45.76M USD |
| Selling, general, and administrative | 14.68M USD | 11.36M USD |
| Operating expenses | 91.29M USD | 57.12M USD |
| Interest income | 6.18M USD | 7.44M USD |
| Depreciation and amortization | 42K USD | 29K USD |
| Operating income | −91.29M USD | −57.12M USD |
| Net income | −85.2M USD | −49.74M USD |
Company facts updated Nov 22, 2026.
Reported history and fiscal-year consensus
Reported history and fiscal-year consensus
Funds reporting this stock among their holdings, ordered by reported position size.
iShares Russell 2000 ETFIWM13.85M0.02%71.54B USD0.19%$256.61-2.88%
Vanguard Morningstar Total Stock Market ETFVTI10.79M0.00%689.3B USD0.03%$340.02-3.52%
Vanguard Extended Market ETFVXF5.16M0.01%30.2B USD0.05%$211.44-3.21%
State Street SPDR S&P Pharmaceuticals ETFXPH4.64M0.93%501.19M USD0.35%$62.15-2.00%
iShares Russell 2000 Growth ETFIWO3.36M0.03%12.73B USD0.24%$320.43-3.57%
Vanguard Russell 2000 ETFVTWO2.73M0.02%16.8B USD0.06%$103.76-2.76%
Schwab U.S. Small-Cap ETFSCHA2.6M0.01%20.45B USD0.03%$30.51-2.83%
T. Rowe Price Small-Mid Cap ETFTMSL2.27M0.07%3.14B USD0.55%$38.96-2.79%
iShares Russell 2000 ETFIWM
Vanguard Morningstar Total Stock Market ETFVTI
Vanguard Extended Market ETFVXF
State Street SPDR S&P Pharmaceuticals ETFXPH
iShares Russell 2000 Growth ETFIWO
Vanguard Russell 2000 ETFVTWO
Schwab U.S. Small-Cap ETFSCHA
T. Rowe Price Small-Mid Cap ETFTMSLAI-generated and delayed market data for informational and educational purposes only. Not investment advice.